Amgen (NASDAQ:AMGN) Upgraded at Wall Street Zen

11 Aug 2026, 01:06 by Doug Wharley · The Cerbat Gem

Wall Street Zen upgraded shares of Amgen (NASDAQ:AMGN – Free Report) from a hold rating to a buy rating in a research report report published on Saturday.

Several other equities analysts have also recently weighed in on AMGN. Daiwa Securities Group lowered their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Royal Bank Of Canada upped their target price on shares of Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Wells Fargo & Company lifted their price target on shares of Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Morgan Stanley boosted their price objective on Amgen from $333.00 to $351.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $371.68.

View Our Latest Stock Report on Amgen

Amgen Stock Performance

Shares of AMGN opened at $417.20 on Friday. The firm has a market capitalization of $225.55 billion, a P/E ratio of 25.93, a PEG ratio of 3.82 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen has a one year low of $269.77 and a one year high of $418.40. The business has a fifty day moving average of $364.54 and a 200 day moving average of $357.03.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen will post 22.78 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. Amgen’s dividend payout ratio is currently 62.65%.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Amgen

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. BlackRock Inc. lifted its position in Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after purchasing an additional 2,261,544 shares during the last quarter. State Street Corp lifted its position in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after purchasing an additional 1,287,310 shares during the last quarter. Capital World Investors grew its stake in shares of Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Company Profile

(Get Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.